IL250270B - Abiraterone acetate formulations and methods of use - Google Patents
Abiraterone acetate formulations and methods of useInfo
- Publication number
- IL250270B IL250270B IL250270A IL25027017A IL250270B IL 250270 B IL250270 B IL 250270B IL 250270 A IL250270 A IL 250270A IL 25027017 A IL25027017 A IL 25027017A IL 250270 B IL250270 B IL 250270B
- Authority
- IL
- Israel
- Prior art keywords
- methods
- abiraterone acetate
- acetate formulation
- formulation
- abiraterone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462052294P | 2014-09-18 | 2014-09-18 | |
US14/707,922 US20150246060A1 (en) | 2013-03-15 | 2015-05-08 | Abiraterone Acetate Formulation and Methods of Use |
PCT/US2015/050889 WO2016044701A1 (en) | 2014-09-18 | 2015-09-18 | Abiraterone acetate formulation and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
IL250270A0 IL250270A0 (en) | 2017-03-30 |
IL250270B true IL250270B (en) | 2021-02-28 |
Family
ID=55533897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL250270A IL250270B (en) | 2014-09-18 | 2017-01-25 | Abiraterone acetate formulations and methods of use |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP3193857A4 (ko) |
JP (1) | JP2017528457A (ko) |
KR (2) | KR102617537B1 (ko) |
CN (1) | CN106687112A (ko) |
AP (1) | AP2017009804A0 (ko) |
AU (1) | AU2015317466A1 (ko) |
BR (1) | BR112017003219A2 (ko) |
CA (1) | CA2958316A1 (ko) |
CO (1) | CO2017002472A2 (ko) |
EA (1) | EA201790650A1 (ko) |
IL (1) | IL250270B (ko) |
MD (1) | MD20170048A2 (ko) |
MX (1) | MX2017003525A (ko) |
PH (1) | PH12017500239A1 (ko) |
SG (1) | SG11201701139YA (ko) |
TN (2) | TN2018000318A1 (ko) |
WO (1) | WO2016044701A1 (ko) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3824908A1 (en) | 2015-04-10 | 2021-05-26 | Capsugel Belgium NV | Abiraterone acetate lipid formulations |
AU2018249608B2 (en) * | 2017-04-07 | 2024-05-02 | Maa Laboratories, Inc. | Methods of improving the solubility and bioavailability of therapeutic agents |
WO2020151633A1 (en) * | 2019-01-25 | 2020-07-30 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical compositions |
CN114026106A (zh) | 2019-03-06 | 2022-02-08 | 普洛拉治疗公司 | 阿比特龙前药 |
CN110742870B (zh) * | 2019-12-04 | 2021-04-20 | 武汉大学 | 醋酸阿比特龙制剂及其制备方法 |
CN111110646A (zh) * | 2020-02-19 | 2020-05-08 | 纳兰迦(上海)生物医药科技有限公司 | 一种低规格醋酸阿比特龙口服制剂的处方及制备方法 |
CN113384542B (zh) * | 2020-03-14 | 2024-03-29 | 鲁南制药集团股份有限公司 | 一种甾体cyp17抑制剂固体分散体的片剂及其制备方法 |
KR20230008780A (ko) * | 2020-05-08 | 2023-01-16 | 얀센 파마슈티카 엔.브이. | 아비라테론 아세테이트 및 니라파립의 조합을 사용한 전립선암의 치료 |
EP3944860A1 (en) | 2020-07-30 | 2022-02-02 | Galenicum Health S.L.U. | Abiraterone for use in a method of treating cancer |
JP2024506382A (ja) | 2021-02-15 | 2024-02-13 | プロペラ セラピューティクス インコーポレイテッド | アビラテロンプロドラッグ |
KR20240044329A (ko) | 2022-09-28 | 2024-04-04 | 한미약품 주식회사 | 아비라테론 아세테이트 및 프레드니솔론을 포함하는 경구용 복합정제 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010121322A1 (en) * | 2009-04-24 | 2010-10-28 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at commercial scale |
GB201207886D0 (en) * | 2012-05-04 | 2012-06-20 | Jagotec Ag | Improvements in or relating to organic compounds |
WO2014009437A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Oxidation stability of abiraterone acetate |
WO2014009436A1 (en) | 2012-07-11 | 2014-01-16 | Sandoz Ag | Nanosuspension of abiraterone acetate |
WO2014009434A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate |
CN102743393A (zh) | 2012-07-27 | 2012-10-24 | 海南盛科生命科学研究院 | 一种含有醋酸阿比特龙的药物组合物及制备工艺 |
KR20180021932A (ko) * | 2013-03-15 | 2018-03-05 | 아이슈티카 인코포레이티드 | 아비라테론 아세테이트 제제 |
-
2015
- 2015-09-18 AP AP2017009804A patent/AP2017009804A0/en unknown
- 2015-09-18 AU AU2015317466A patent/AU2015317466A1/en not_active Abandoned
- 2015-09-18 TN TNP/2018/000318A patent/TN2018000318A1/en unknown
- 2015-09-18 WO PCT/US2015/050889 patent/WO2016044701A1/en active Application Filing
- 2015-09-18 EA EA201790650A patent/EA201790650A1/ru unknown
- 2015-09-18 BR BR112017003219A patent/BR112017003219A2/pt not_active IP Right Cessation
- 2015-09-18 EP EP15842591.8A patent/EP3193857A4/en not_active Withdrawn
- 2015-09-18 CA CA2958316A patent/CA2958316A1/en active Pending
- 2015-09-18 KR KR1020237001893A patent/KR102617537B1/ko active IP Right Grant
- 2015-09-18 CN CN201580050453.8A patent/CN106687112A/zh active Pending
- 2015-09-18 MX MX2017003525A patent/MX2017003525A/es unknown
- 2015-09-18 JP JP2017512783A patent/JP2017528457A/ja active Pending
- 2015-09-18 SG SG11201701139YA patent/SG11201701139YA/en unknown
- 2015-09-18 MD MDA20170048A patent/MD20170048A2/ro not_active Application Discontinuation
- 2015-09-18 KR KR1020177008938A patent/KR102491439B1/ko active IP Right Grant
- 2015-09-18 TN TN2017000098A patent/TN2017000098A1/en unknown
-
2017
- 2017-01-25 IL IL250270A patent/IL250270B/en active IP Right Grant
- 2017-02-09 PH PH12017500239A patent/PH12017500239A1/en unknown
- 2017-03-15 CO CONC2017/0002472A patent/CO2017002472A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3193857A4 (en) | 2018-04-11 |
WO2016044701A1 (en) | 2016-03-24 |
KR102491439B1 (ko) | 2023-01-25 |
TN2018000318A1 (en) | 2020-01-16 |
BR112017003219A2 (pt) | 2017-11-28 |
AP2017009804A0 (en) | 2017-03-31 |
CN106687112A (zh) | 2017-05-17 |
EP3193857A1 (en) | 2017-07-26 |
KR20230014878A (ko) | 2023-01-30 |
KR20170070025A (ko) | 2017-06-21 |
PH12017500239A1 (en) | 2017-07-03 |
IL250270A0 (en) | 2017-03-30 |
MX2017003525A (es) | 2017-06-21 |
AU2015317466A1 (en) | 2017-02-23 |
CA2958316A1 (en) | 2016-03-24 |
MD20170048A2 (ro) | 2017-08-31 |
TN2017000098A1 (en) | 2018-10-19 |
SG11201701139YA (en) | 2017-03-30 |
CO2017002472A2 (es) | 2017-07-11 |
KR102617537B1 (ko) | 2023-12-22 |
EA201790650A1 (ru) | 2017-07-31 |
JP2017528457A (ja) | 2017-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20210526T8 (hr) | Oksisteroli i postupci za njihovu uporabu | |
IL250415B (en) | Antibodies against pd-l and methods of using them | |
IL289976A (en) | Oxysterols and methods of using them | |
IL250270A0 (en) | Abiraterone acetate formulations and methods of use | |
HK1255500A1 (zh) | 氧固醇及其使用方法 | |
SG11201703298SA (en) | Activated bifidobacteria and methods of use thereof | |
GB201421847D0 (en) | Dispensers and methods of use thereof | |
EP3157528A4 (en) | Oxysterols and methods of use thereof | |
GB201417048D0 (en) | Occupancy-control device and methods of use | |
IL280082A (en) | Neuroactive steroid solutions and methods of using them | |
EP3190886A4 (en) | Compositions and methods of use thereof | |
SG11201605915WA (en) | Furo-3-carboxamide derivatives and methods of use | |
HK1243404A1 (zh) | 色酰胺組合物和使用方法 | |
IL246944B (en) | A process for the preparation of abiraterone acetate and its intermediates | |
GB201408171D0 (en) | Formulation and method of manufacture | |
GB2537518B (en) | Settable compositions and methods of use | |
GB201509977D0 (en) | Dispensers and methods of use thereof | |
AU2014905266A0 (en) | Formulation and method of use | |
GB201408738D0 (en) | Components and methods for formulation of components | |
AU2014905067A0 (en) | Compositions and methods of use | |
AU2014904885A0 (en) | Device and method of use | |
GB201416797D0 (en) | Contianer and method of use thereof | |
AU2014902829A0 (en) | Compositions and Methods of Use | |
GB201419844D0 (en) | An aircraft and method of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed |